The University of California, Davis Cancer Clinical Trials Program is a dynamic and diverse group of university and private practice physicians and nurses who are very successful at NCI-sponsored cooperative group clinical trials. The Clinical Trials Program is housed in our 55,000 square foot cancer treatment center. Multidisciplinary clinics provide to patients a balance of opinions and support for entry into protocol therapy. The success of our outreach program in the first four years of SWOG membership is presented as a continuation of the CGOP program and a transference of four competent and established CGOP sites into a formal consortium agreement. The consortia members include the largest prepaid HMO in the U.S.A., the largest military hospital on the West Coast, the only clinical trials organization in Northern Nevada, and a 6-member private practice group with impressive credentials. The broadest objective of this proposal is to provide protocol governed therapy to the Central California population. However, we have aims specific to U.C. Davis. 1) To enhance the understanding of the biology of cancer in patients enrolled in SWOG protocols, specifically in urologic oncology and hematologic oncology using flow cytometry, molecular biology and cytogenetics. 2) To provide clinical science sophistication in urologic oncology, lung cancer, and hematologic oncology. 3) To improve the access of protocol-governed therapy to underserved minority patients in our area. 4) To increase cancer control activities, especially in ethnic minority patients. We will accomplish these goals within a sophisticated and integrated management team that includes a balance of enthusiasm and rigid quality control activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA046441-06A1
Application #
3558756
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-01-01
Project End
1997-12-31
Budget Start
1993-02-01
Budget End
1993-12-31
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Advani, Ranjana H; Hong, Fangxin; Fisher, Richard I et al. (2015) Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol 33:1936-42
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 129 publications